Abstract
It is well established that human mast cell proliferation and maturation are regulated by kit ligand (stem cell factor). Little is known, however, about how these two processes are negatively regulated and thus, how mast cell number is controlled in normal and pathologic conditions. We therefore first hypothesized that SCF-dependent human mast cells would undergo programmed cell death (apoptosis) on removal of SCF as has been shown for growth factor-dependent rodent mast cells. We then examined whether SCF acts as a survival factor through the regulation of the bcl-2 family of apoptosis-regulatory genes. As hypothesized, elimination of SCF from primary peripheral blood-derived human mast cell cultures resulted in a significant apoptotic process. During apoptosis, down-regulation of the two apoptosis-regulatory proteins Bcl-2 and Bcl-XLwas observed. Moreover, a deregulated expression of these two proteins was found in two human mast cell lines which are SCF-independent. Thus, SCF functions as a survival factor by repressing apoptosis of human mast cells through Bcl-2 and Bcl-XL. Deregulated expression of these antiapoptotic proteins may contribute to proliferation and accumulation of mast cells in certain forms of systemic mast cell disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Rottem M, Okada T, Goff JP, Metcalfe DD: Mast cells cultured from peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc∈RI-cell population. Blood 84:2489-2996, 1994
Mekori YA, Hartmann K, Metcalfe DD: Mast cell apoptosis and its regulation. In Signal Transduction in Mast Cells and Basophils, E Razin, J Rivera (eds). New York, Springer-Verlag, 1999, pp 85-94
Finotto S, Mekori YA, Metcalfe DD: Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor. J Clin Invest 99:1721-1728, 1997
Cory S: Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13:513-543, 1995.
Silva M, Richard C, Benito A, Sanz C, Olalla I L, Fernandez-Luna JL: Expression of Bcl-X in erythroid precursors from patients with polycythemia vera. N Engl J Med 338:564-571, 1998
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Kushimizu U, et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736-1740, 1993
Mekori YA, Oh CK, Dastych J, Goff JP, Adachi S, Bianchine PJ, Worobec A, Semere T, Pierce JH, Metcalfe DD: Characterization of a mast cell line that lacks the extracellular domain of membrane c-kit. Immunology 90:518-525, 1997
Maurer M, Tsai M, Metz M, Fish S, Korsmeyer SJ, Galli SJ: A role for bax in the regulation of apoptosis in mouse mast cells. J Invest Dermatol 114:1205-1206, 2000
Sanz C, Benito A, Silva M, Albella B, Richard C, Segovia JC, et al.: The expression of Bcl-x is downregulated during differentiation of human hematopoietic progenitor cells. Blood 89:3199-3204, 1997
Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88: 1576-1582, 1996
Taylor ML, Metcalfe DD: Kit signal transduction. Hematol/Oncol Clin North Am 14:517-535, 2000
Cervero C, Escribano L, San Miguel JF, Diaz-Augustin B, Bravo P, Villarubia J, Garcia-Sanz R, Velsaco JL, Herrera P, Vargas M, Gonzales M, Navarro JL, Orfao A: Expression of Bcl-2 by human marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 60:191-195, 1999